207_Combined course Presentations

Keynote-024: Pembrolizumab vs Chemotherapy as first line therapy in stage IV NSCLC



Phase III trial

 Pembrolizumab vs Platinum based doublet



305 patients enrolled

 All patients had a PD-L1 expression on

at least 50% of the tumor cells

Reck M. et al. NEJM 2016